BioSpace News Archive

Can-Fite BioPharma Ltd. today announced that pre-clinical studies with skin cells, modeling psoriasis in humans, show that Piclidenoson, the Company’s drug candidate for the treatment of psoriasis, destroys pathological skin cells.

Endo International plc (NASDAQ:ENDP) announced today the publication of data from a population pharmacokinetic (PK) modeling and simulation study, evaluating potential dosing flexibility of AVEED® (testosterone undecanoate) in hypogonadal males.

OraSure Technologies, Inc., a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced that its InteliSwab® COVID-19 rapid tests detect the Omicron variant as effectively as they detect the original SARS-CoV-2 strain and other previous variants of concern, including Delta, Alpha, Beta and Gamma.

The Company thanks Mr. Schwartz for his valuable contributions and wishes him every success in his future endeavors.

Myomo, Inc. announced that Paul Gudonis, Myomo’s chairman and chief executive officer, and David Henry, Myomo’s chief financial officer, will present at the Sidoti Winter Small Cap Conference, which is being held virtually from January 19 to January 20, 2022.

Intellipharmaceutics International Inc. and, a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, announced with great sadness that Kenneth Keirstead, a member of the Company’s Board of Directors, has passed away.

The Supreme Court of the United States today issued a temporary stay blocking the Biden administration’s federal vaccine mandate for employers with over 100 employees.

Corvus Pharmaceuticals, Inc. (Corvus or the Company) (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that its partner in China, Angel Pharmaceuticals Ltd. (Angel Pharma), has treated the first patient in its Phase 1/1b clinical trial of Corvus’ small molecule ITK inhibitor CPI-818 for the treatment of relapsed/refractory T-cell lymphomas (TCL) in China.

The U.S. digital health market has been projected to experience various growth opportunities in the foreseeable years.

Transparency Market Research has published a new report on the global hemostasis valves market for the forecast period of 2019–2027. According to the report, the global hemostasis valves market was valued at ~US$ 135 Mn in 2018, and is projected to expand at a CAGR of 4.5% from 2019 to 2027.